PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 297.6K (Avg.)
-1.36 | -1.31
Shows the trajectory of a company's cash-generation capacity. Consistent growth in operating and free cash flow suggests a robust, self-funding business model—crucial for value investors seeking undervalued, cash-rich opportunities.
-15.16%
Both yoy net incomes decline, with GNPX at -88.41%. Martin Whitman would view it as a broader sector or cyclical slump hitting profits.
8.11%
D&A growth well above GNPX's 3.85%. Michael Burry would suspect heavier depreciation burdens that might erode net income unless top-line follows suit.
14.88%
Deferred tax of 14.88% while GNPX is zero at 0.00%. Bruce Berkowitz would see a partial difference that can matter for future cash flow if large in magnitude.
33.33%
SBC growth well above GNPX's 50.45%. Michael Burry would flag major dilution risk vs. competitor’s approach.
-359.86%
Negative yoy working capital usage while GNPX is 114.40%. Joel Greenblatt would see more free cash if revenue remains unaffected, giving a short-term advantage.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-185.03%
Negative yoy usage while GNPX is 35.50%. Joel Greenblatt would see a short-term advantage in freeing up capital unless competitor invests effectively in these lines.
-14.88%
Both negative yoy, with GNPX at -5061.19%. Martin Whitman would suspect an overall environment of intangible cleanup or shifting revaluations for the niche.
-25.31%
Both yoy CFO lines are negative, with GNPX at -93.14%. Martin Whitman would suspect cyclical or cost factors harming the entire niche’s cash generation.
-2962.50%
Both yoy lines negative, with GNPX at -15222.52%. Martin Whitman would suspect a cyclical or broad capital spending slowdown in the niche.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-2962.50%
Both yoy lines negative, with GNPX at -1633.32%. Martin Whitman suspects a broader cyclical shift away from heavy investing across the niche.
56.30%
Debt repayment growth of 56.30% while GNPX is zero at 0.00%. Bruce Berkowitz sees a mild advantage that can reduce interest costs unless expansions demand capital here.
23135.79%
Stock issuance far above GNPX's 1474.38%. Michael Burry flags a significant dilution risk vs. competitor’s approach unless ROI is very high.
100.00%
Buyback growth of 100.00% while GNPX is zero at 0.00%. Bruce Berkowitz sees a modest per-share advantage that might accumulate if the stock is below intrinsic value.